Utility of scoring function customization in docking-based virtual screening approaches

Govardhan A. Balaji, Vitukudi N. Balaji and Shashidhar N. Rao* Department of Chemistry, St Joseph’s College, 36 Langford Road, Bangalore 560 027, India Structure Directed Molecular Design, Jubilant Biosys Ltd, #96, Industrial Suburb II Stage, Yeshwantpur, Bangalore 560 022, India Tripos – A CertaraTM Company, 1699 South Hanley Road, St Louis MO 63144, USA Present address: Department of Chemistry and Chemical Biology, Rutgers University, Piscataway, NJ 08554, USA

[1]  Kimito Funatsu,et al.  Systematic generation of chemical structures for rational drug design based on QSAR models. , 2011, Current computer-aided drug design.

[2]  W W Wilkerson,et al.  Nonsymmetrically substituted cyclic urea HIV protease inhibitors. , 1997, Journal of medicinal chemistry.

[3]  Zhilong Xiu,et al.  Rescoring ligand docking poses. , 2010, Current opinion in drug discovery & development.

[4]  M. Katharine Holloway,et al.  X-Ray Crystal Structure of the HIV Protease Complex with L-700,417, an Inhibitor with Pseudo C2 Symmetry , 1991 .

[5]  C H Chang,et al.  Design, synthesis, and evaluation of tetrahydropyrimidinones as an example of a general approach to nonpeptide HIV protease inhibitors. , 1997, Journal of medicinal chemistry.

[6]  Alexander Golbraikh,et al.  Predictive QSAR modeling workflow, model applicability domains, and virtual screening. , 2007, Current pharmaceutical design.

[7]  P. Lam,et al.  Cyclic HIV protease inhibitors: design and synthesis of orally bioavailable, pyrazole P2/P2' cyclic ureas with improved potency. , 1998, Journal of medicinal chemistry.

[8]  B. Tidor,et al.  Rational Approaches to Improving Selectivity in Drug Design , 2012, Journal of medicinal chemistry.

[9]  I. De Lucca,et al.  Stereospecific synthesis, structure-activity relationship, and oral bioavailability of tetrahydropyrimidin-2-one HIV protease inhibitors. , 1999, Journal of medicinal chemistry.

[10]  Dariusz Plewczynski,et al.  Can we trust docking results? Evaluation of seven commonly used programs on PDBbind database , 2011, J. Comput. Chem..

[11]  L. Bacheler,et al.  Potent cyclic urea HIV protease inhibitors with 3-aminoindazole P2/P2' groups. , 1998, Bioorganic & medicinal chemistry letters.

[12]  Woody Sherman,et al.  New hypotheses about the structure–function of proprotein convertase subtilisin/kexin type 9: Analysis of the epidermal growth factor‐like repeat A docking site using WaterMap , 2010, Proteins.

[13]  P. Jadhav,et al.  Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV. , 1997, Journal of medicinal chemistry.

[14]  T Klabunde,et al.  Chemogenomics approaches to G-protein coupled receptor lead finding. , 2006, Ernst Schering Research Foundation workshop.

[15]  William Seibel,et al.  Theoretical and practical considerations in virtual screening: a beaten field? , 2008, Current medicinal chemistry.

[16]  Bohdan Waszkowycz,et al.  Towards improving compound selection in structure-based virtual screening. , 2008, Drug discovery today.

[17]  Chong-Hwan Chang,et al.  Improved P1/P1' substituents for cyclic urea based HIV-1 protease inhibitors: synthesis, structure-activity relationship, and X-ray crystal structure analysis. , 1997, Journal of medicinal chemistry.

[18]  Beat Ernst,et al.  Drug discovery today. , 2003, Current topics in medicinal chemistry.

[19]  Ajay N. Jain,et al.  Virtual screening in lead discovery and optimization. , 2004, Current opinion in drug discovery & development.

[20]  Alexander Tropsha,et al.  Application of QSAR and shape pharmacophore modeling approaches for targeted chemical library design. , 2011, Methods in molecular biology.

[21]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[22]  Jordi Mestres,et al.  Guided docking approaches to structure-based design and screening. , 2004, Current topics in medicinal chemistry.

[23]  Eric J Martin,et al.  Target-biased scoring approaches and expert systems in structure-based virtual screening. , 2004, Current opinion in chemical biology.

[24]  Maria João Ramos,et al.  Virtual screening of compound libraries. , 2009, Methods in molecular biology.

[25]  Ajay N. Jain,et al.  Customizing scoring functions for docking , 2008, J. Comput. Aided Mol. Des..

[26]  Chong-Hwan Chang,et al.  Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas. , 1996, Journal of medicinal chemistry.

[27]  Herbert Köppen.  Virtual screening - what does it give us? , 2009, Current opinion in drug discovery & development.

[28]  L. Bacheler,et al.  The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: modifications of the P1/P1' residues. , 1998, Bioorganic & medicinal chemistry letters.

[29]  Didier Rognan,et al.  Comparative evaluation of eight docking tools for docking and virtual screening accuracy , 2004, Proteins.

[30]  J L Meek,et al.  Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies. , 1998, Journal of medicinal chemistry.

[31]  K. Abromeit.  Music Received , 2023, Notes.

[32]  Functionalized aliphatic P2/P2′ analogs of HIV-1 protease inhibitor DMP323 , 1997 .

[33]  R. Cramer,et al.  Validation of the general purpose tripos 5.2 force field , 1989 .

[34]  Ajay N. Jain.  Surflex-Dock 2.1: Robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search , 2007, J. Comput. Aided Mol. Des..

[35]  Michael Nilges,et al.  Comparative Evaluation of 3D Virtual Ligand Screening Methods: Impact of the Molecular Alignment on Enrichment , 2010, J. Chem. Inf. Model..

[36]  Campbell McInnes,et al.  Virtual screening strategies in drug discovery. , 2007, Current opinion in chemical biology.

[37]  S. P. Seitz,et al.  Increased antiviral activity of cyclic urea HIV protease inhibitors by modifying the P1/P1' substituents. , 1999, Bioorganic & medicinal chemistry letters.

[38]  P. Jadhav,et al.  Preparation and structure-activity relationship of novel P1/P1'-substituted cyclic urea-based human immunodeficiency virus type-1 protease inhibitors. , 1996, Journal of medicinal chemistry.

[39]  Gisbert Schneider,et al.  Trends in virtual combinatorial library design. , 2002, Current medicinal chemistry.

[40]  Gerhard Klebe,et al.  Recent developments in structure-based drug design , 2000, Journal of Molecular Medicine.

[41]  L. Bacheler,et al.  Unsymmetrical cyclic ureas as HIV-1 protease inhibitors: novel biaryl indazoles as P2/P2' substituents. , 1999, Bioorganic & medicinal chemistry letters.

[42]  Brian B. Masek,et al.  Virtual Screening for R-Groups, including Predicted pIC50 Contributions, within Large Structural Databases, Using Topomer CoMFA , 2008, J. Chem. Inf. Model..

[43]  A. Debnath,et al.  Three-dimensional quantitative structure-activity relationship study on cyclic urea derivatives as HIV-1 protease inhibitors: application of comparative molecular field analysis. , 1999, Journal of medicinal chemistry.

[44]  Jia Jia,et al.  Comparative analysis of machine learning methods in ligand-based virtual screening of large compound libraries. , 2009, Combinatorial chemistry & high throughput screening.

[45]  W C Guida,et al.  The significance of chirality in drug design and development. , 2011, Current topics in medicinal chemistry.

[46]  J. Bajorath,et al.  Docking and scoring in virtual screening for drug discovery: methods and applications , 2004, Nature Reviews Drug Discovery.

[47]  Ajay N. Jain.  Bias, reporting, and sharing: computational evaluations of docking methods , 2008, J. Comput. Aided Mol. Des..

[48]  L. Bacheler,et al.  Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues. , 1998, Journal of medicinal chemistry.

[49]  Ajay N. Jain.  Effects of protein conformation in docking: improved pose prediction through protein pocket adaptation , 2009, J. Comput. Aided Mol. Des..

[50]  René Thomsen,et al.  MolDock: a new technique for high-accuracy molecular docking. , 2006, Journal of medicinal chemistry.

[51]  Meir Glick,et al.  The role of computational methods in the identification of bioactive compounds. , 2011, Current opinion in chemical biology.

[52]  Dariusz Plewczynski,et al.  VoteDock: Consensus docking method for prediction of protein–ligand interactions , 2011, J. Comput. Chem..

[53]  Christian Lemmen,et al.  Computational methods for the structural alignment of molecules , 2000, J. Comput. Aided Mol. Des..

[54]  R. Kroemer.  Structure-based drug design: docking and scoring. , 2007, Current protein & peptide science.

[55]  W. Sherman,et al.  Thermodynamic analysis of water molecules at the surface of proteins and applications to binding site prediction and characterization , 2011, Proteins.

[56]  Maria A Miteva,et al.  Fast structure-based virtual ligand screening combining FRED, DOCK, and Surflex. , 2005, Journal of medicinal chemistry.

[57]  L. Bacheler,et al.  Synthesis, antiviral activity and pharmacokinetics of P1/P1' substituted 3-aminoindazole cyclic urea HIV protease inhibitors. , 2003, Bioorganic & medicinal chemistry letters.

[58]  Ajay N. Jain.  Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. , 2003, Journal of medicinal chemistry.

[59]  HIV protease inhibitory bis-benzamide cyclic ureas: a quantitative structure-activity relationship analysis. , 1996, Journal of medicinal chemistry.